Rebound of macular edema after intravitreal bevacizumab therapy in eyes with macular edema secondary to branch retinal vein occlusion

Retina

Volumn 31, Issue 6, 2011, Pages 1075-1082

  Yasuda, Shunsuke ^a   Kondo, Mineo ^a   Kachi, Shu ^a   Ito, Yasuki ^a   Terui, Takayuki ^a   Ueno, Shinji ^a   Terasaki, Hiroko ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

bevacizumab; Branch retinal vein occlusion; macular edema; rebound; vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB;

ADULT; ARTICLE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; RECURRENT DISEASE; RETINA FOVEA; RETINA MACULA EDEMA; RETINA VEIN OCCLUSION; VISUAL ACUITY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; FEMALE; FOVEA CENTRALIS; HUMANS; INCIDENCE; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; RECURRENCE; RETINAL VEIN OCCLUSION; RISK FACTORS; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 79958281477     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e318206cf4b     Document Type: Article

References (31)

1. Gutman FA. Macular edema in branch retinal vein occlusion: prognosis and management. Trans Am Acad Ophthalmol Otolaryngol 1977;83:488-495.
2. Hoerauf H. Branch retinal vein occlusion. In: Joussen AM, Gardner TW, Kirchhof B, Ryan SJ. eds. Retinal Vascular Disease. Philadelphia, PA: Springer; 2007:467-506.
3. Rehak J, Rehak M. Branch retinal vein occlusion: pathogen-esis, visual prognosis, and treatment modalities. Curr Eye Res 2008;33:111-131. (Pubitemid 351302200)
4. The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 1984;98:271-282.
5. Arnarsson A, Stefánsson E. Laser treatment and the mecha-nism of edema reduction in branch retinal vein occlusion. Invest Ophthalmol Vis Sci 2000;41:877-879. (Pubitemid 30158902)
6. McIntosh RL, Mohamed Q, Saw SM, Wong TY. Interventions for branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology 2007;114:835-854.
7. Jonas JB, Akkoyun I, Kamppeter B, Kreissig I, Degenring RF. Branch retinal vein occlusion treated by intravitreal triamcinolone acetonide. Eye 2005;19:65-71. (Pubitemid 40192642)
8. Avitabile T, Longo A, Reibaldi A. Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. Am J Ophthalmol 2005; 140:695-702.
9. Ozkiris A, Evereklioglu C, Erkilic K, Dogan H. Intravitreal triamcinolone acetonide for treatment of persistent macular oedema in branch retinal vein occlusion. Eye 2006;20: 13-17. (Pubitemid 43090586)
10. Scott IU, Ip MS, VanVeldhuisen PC, et al.; SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Cortico-steroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 2009;127:1115-1128.
11. Osterloh MD, Charles S. Surgical decompression of branch retinal vein occlusions. Arch Ophthalmol 1988;106:1469-1471.
12. Opremcak EM, Bruce RA. Surgical decompression of branch retinal vein occlusion via arteriovenous crossing sheathotomy: aprospective review of 15 cases. Retina 1999; 19:1-5. (Pubitemid 30387533)
13. Yamamoto S, Saito W, Yagi F, Takeuchi S, Sato E, Mizunoya S. Vitrectomy with or without arteriovenous adventitial shea-thotomy for macular edema associated with branch retinal vein occlusion. Am J Ophthalmol 2004;138:907-914. (Pubitemid 40040004)
14. Kumagai K, Furukawa M, Ogino N, Uemura A, Larson E. Long-term outcomes of vitrectomy with or without arteriove-nous sheathotomy in branch retinal vein occlusion. Retina 2007;27:49-54. (Pubitemid 46095830)
15. Rabena MD, Pieramici DJ, Castellarin AA, Nasir MA, Avery RL. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina 2007; 27: 419-425. (Pubitemid 46624280)
16. Kreutzer TC, Alge CS, Wolf AH, et al. Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol 2008;92:351-355. (Pubitemid 351363529)
17. Wu L, Arevalo JF, Roca JA, et al; Pan-American Collaborative Retina Study Group (PACORES). Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up. Retina 2008;28:212-219. (Pubitemid 351643150)
18. Kriechbaum K, Michels S, Prager F, et al. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol 2008;92:518-522. (Pubitemid 351497981)
19. Noma H, Minamoto A, Funatsu H, et al. Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2006;244:309-315.
20. Noma H, Funatsu H, Yamasaki M, et al. Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. Eye 2008;22:42-48.
21. Adamis AP, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina 2005;25:111-118. (Pubitemid 40365933)
22. Campochiaro PA. Seeing the light: new insights into the molecular pathogenesis ofretinal diseases. J Cell Physiol 2007; 213:348-354. (Pubitemid 47509712)
23. Jaissle GB, LeitritzM, GeliskenF, ZiemssenF, Bartz-SchmidtKU, Szurman P. One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2009;247:27-33.
24. Prager F, Michels S, Kriechbaum K, et al. Intravitreal bevacizumab (Avastin) for macular edema secondary to retinal vein occlusion\twelve-month results of a prospective clinical trial. Br J Ophthalmol 2008;93:452-456.
25. Kondo M, Kondo N, Ito Y, et al. Intravitreal injection of bevacizumab for macular edema secondary to BRVO: results after 12-months and multiple regression analysis. Retina 2009; 29:1242-1248.
26. Wu L, Arevalo JF, Berrocal MH, et al. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to branch retinal vein occlusions: results of the Pan American Collaborative Retina Study Group at 24 months. Retina 2009;29:1396-1403.
27. Matsumoto Y, Freund KB, Peiretti E, Cooney MJ, Ferrara DC, Yannuzzi LA. Rebound macular edema following bevacizu-mab (Avastin) therapy for retinal venous occlusive disease. Retina 2007;27:426-431. (Pubitemid 46624281)
28. Ishikawa K, Kondo M, Ito Y, et al. Correlation between focal macular electroretinograms and angiographic findings after photodynamic therapy. Invest Ophthalmol Vis Sci 2007;48: 2254-2259. (Pubitemid 351261303)
29. Sugita T, Kondo M, Piao CH, Ito Y, Terasaki H. Correlation between macular volume and focal macular electroretinogram in patients with retinitis pigmentosa. Invest Ophthalmol Vis Sci 2008;49:3551-3558.
30. Costa RA, Calucci D, Skaf M, et al. Optical coherence tomography 3: automatic delineation of the outer neural retinal boundary and its influence on retinal thickness measurements. Invest Ophthalmol Vis Sci 2004;45:2399-2406. (Pubitemid 38902615)
31. Kakinoki M, Sawada O, Sawada T, Kawamura H, Ohji M. Comparison of macular thickness between Cirrus HD-OCT and Stratus OCT. Ophthalmic Surg Lasers Imaging 2009;40:135-140.